Less than a tenth of patients eligible to benefit from obesity jabs like Wegovy are able to get them, states the World Health Organization as it issues its initial guidance on the medications.
Given over a billion individuals worldwide currently living with obesity, it is advocating for more widespread and fairer access to these injectable treatments.
Based on estimates, more than two billion will be living with obesity by 2030 unless action is taken.
"Our latest guidelines affirms that obesity is a chronic disease that can be managed with comprehensive and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key hurdles to broad access to the jabs that can assist patients in reducing substantial weight, explains the agency.
Weight-Loss Drug Scarcity
Even in the current most optimistic scenario, the manufacturing of these medications might only reach around 100 million people – less than 10% of the global need, per the WHO.
The recommendation encourages governments and firms to expand availability, by measures including licensing agreements.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is scheduled to end in multiple nations in 2026.
How Obesity Jabs Work
The injections imitate a natural hormone to reduce digestion speed, suppress the appetite and enhance satiety so people reduce food intake.
Patients commonly start to lose weight within a few weeks of beginning the regular doses.
Research points to people may put most of the weight back on after a year of halting the treatment, when their usual hunger come back.
Being overweight or obese raises your risk for developing health problems, like diabetes, heart disease, stroke, and certain cancers.
Obesity concerns individuals in every country and was responsible for over three and a half million deaths worldwide in 2024, according to the health agency.
